Susan G. Komen for the Cure® Ambassador René Syler speaks with Dr. Anne Moore, Medical Director of Breast Oncology Program at the Weill Medical College of Cornell University and Attending Physician at The New York Presbyterian Hospital, about how to cope with the fear of a recurrence of breast cancer.
Views: 566 Susan G. Komen®
Dr. Margileth defines a triple negative breast cancer as breast cancers that have negative estrogen receptor, negative progesterone receptor and negative HER2/neu gene. He further describes treatment options and risk of recurrence. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. *** This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Views: 12400 Breast Cancer Answers®
Dr. Daniel Hayes discusses new research on the risk of breast cancer recurrence after pregnancy from the 2017 ASCO Annual Meeting. Learn more about this study at http://www.cancer.net/blog/2017-06/asco-annual-meeting-2017-news-breast-cancer-prostate-cancer-trk-fusion-protein-inhibition-using
Views: 213 Cancer.Net
www.DelgadoProtocol.com Dr. Thierry Hertoghe, 3rd generation endocrinologist, discusses the conclusion of studies regarding the safety, efficacy, and increased chance of sustained remission/decrease in recurrence when using hormone therapy after breast cancer. @ the 2012 A4M Las Vegas. www.DelgadoProtocol.com
Views: 284 Dr. Nick Delgado
Views: 275 LOCAL 12
http://www.howdini.com/howdini-video-7257883.html How to cope with fear of breast cancer recurrence Once a woman has undergone treatment for breast cancer, often her biggest concern is whether the cancer will appear in the opposite breast or spread to other areas of the body. Dr. Anne Moore, a leading breast oncologist, shares important information to help breast cancer survivors cope with the fear of recurrence.
Views: 1614 Howdini
Presented by Jean Harvey, PhD, RD at the Vermont Cancer Center's 16th Annual Breast Cancer Conference (October 4, 2013). For more information about the Breast Cancer Conference, visit http://www.uvm.edu/medicine/vtbreastcancerconference.
Views: 1302 The University of Vermont Cancer Center
A study out of Singapore, published in Annals of Oncology in March of 2012, showed that breast cancer patients treated with chemotherapy had symptoms of chemobrain manifested by memory loss, difficulty in decision making and speech problems. Patients were generally not aware they had symptoms because they attributed them to fatigue, anxiety, and mood changes related to the physical side effects of chemotherapy. They were unable to fulfill their duties as mothers and wives because of their cognitive defects. Chemotherapy is overused in this country in both people with mild disease that don't really benefit much from treatment and those who are stage 4 and only respond between 2-3% of the time. It is interesting that oncologists generally don't take the same aggressive treatment themselves that they recommend to their patients. Take Dr. Saputo's Breast Cancer Health Assessment Once you have breast cancer you need to know the best strategies to slow down or reverse its growth. In Dr. Saputo's Breast Cancer Health Assessment we will ask you about the type of breast cancer you have, what treatment you've considered or completed, whether or not you're interested in CAM approaches to treatment, and important lifestyle factors that could have an impact on how your cancer will affect you. You will immediately be emailed back audios and videos Dr. Saputo believes will guide you to information that can help you manage your cancer and support the body's immune defenses. There is a lot we can do to prevent activating cancer genes and to protect us from developing breast cancer. Most breast cancers are epigenetic, not genetic! http://doctorsaputo.com/a/breast-cancer-health-assessment
Views: 238 DoctorSaputo
*DCIS Diagnosis & The Oncotype Breast Cancer Assay for DCIS* Genomic Health, Inc. reported positive results from an initial validation study of Oncotype DX® in patients suffering from a pre-invasive form of breast cancer, also known as ductal carcinoma in situ (DCIS). This is the second largest, independent clinical study of Oncotype DX. The Ontario DCIS Study Group in Canada conducted this clinical study which met its primary endpoint by substantiating that the Oncotype DX DCIS Score™ can predict the risk of local recurrence. Local recurrence indicates either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. DCIS is a stage zero breast cancer that affects 1 out of every 5 women in the U.S. The study revealed that approximately 80% of women diagnosed with DCIS currently receive unnecessary aggressive therapy, while others in need of it often miss the chance of undergoing the advance treatment. This often causes cancer to proliferate, which could have otherwise been avoided with proper treatment. However, the above-mentioned study showed that Oncotype DX can predict individual risk of recurrence and thereby help in taking suitable treatment decisions. This not only leads to timely treatment decisions but also reduces healthcare costs. The aforementioned study results represent the largest genomic study in DCIS to date. These results reaffirm the inferences of the previously-released validation study performed by the ECOG-ACRIN Cancer Research Group. This is the first time the Oncotype DX DCIS Score has succeeded in predicting the risk of local recurrence in a group of patients treated with radiation therapy in clinical practice. The study involved more than 1,200 patients diagnosed with DCIS between 1994 and 2003. Researchers from Genomic Health collaborated with the Ontario DCIS Study Group to examine the tumor samples collected from these patients. The patient group constituted both patients treated with surgery alone and those treated with surgery plus radiation. Genomic Health and the Ontario DCIS Study Group plans to submit the results from this study at the 2014 San Antonio Breast Cancer Symposium in December. Recently, a clinical decision impact study presented at the American Society of Clinical Oncology revealed that the Oncotype DX DCIS Score results have changed treatment recommendations for 1 out of 3 patients with DCIS, highlighting the need for optimizing treatment of DCIS. The Oncotype DX DCIS Score looks at 12 genes within a tumor sample to reveal the aggressiveness of the disease. Join Medical Director Dr. Jay Harness along with co-founders of BreastCancerAnswers.com Todd Hartley & Wendy Hartley as they discuss getting diagnosed with DCIS and the Oncotype DX Breast Cancer Assay for DCIS patients. The live event will take place on April 2nd at 9 am PT/12 pm ET. To watch it on your mobile device, go to http://www.youtube.com/watch?v=zLAUX2x45Hc #ODX #DCIS #BreastCancer
Views: 3213 Breast Cancer Answers®
Matteo Lambertini talks about the long term results analysis from an international study exploring the safety of pregnancy in patients with an history of ER positive breast cancer. At 10 years, no significant difference was observed in DFS or OS. Abstract as referenced in the ASCO 2017 programme: LBA 10066: Safety of pregnancy in patients with history of estrogen receptor positive breast cancer Long-term follow-up analysis from a multi center study. Produced by the European Society for Medical Oncology http://www.esmo.oncologypro.org
Views: 325 European Society for Medical Oncology
STOCKHOLM -- Local recurrence in early breast cancer occurred 35% less often in women who received synchronous chemoradiation rather than sequential therapy, long-term follow-up data from a large clinical trial showed. Medpage Today: http://medpagetoday.com Online CME - Continuing medical education: http://www.medpagetoday.com/cme/ Latest medical news: http://www.medpagetoday.com/latest/ The MedPage Today app: iOS: https://goo.gl/JKrkHq Android: https://play.google.com/store/apps/details?id=com.medpagetoday.medpage MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday Medpage Today on Facebook: https://www.facebook.com/MedPageToday
Views: 54 MedPage Today
Cancer cell dies when you eat these 7 foods, time to start eating them | 7 Anti Cancer Foods An anti-cancer diet is an important strategy you can use to reduce your risk of cancer. The American Cancer Society recommends, for example, that you eat at least five servings of fruits and vegetables daily and eat the right amount of food to stay at a healthy weight. In addition, researchers are finding that certain foods that prevent cancer may be an important part of an anti-cancer diet. 1. Carrots Like kale and spinach, carrots pack carotenoids, an antioxidant group that may help prevent rectal cancer. Evidence suggests that consuming high levels of carotenoids from fruits and vegetables can be protective in relation to cancer recurrence. Studies show that these antioxidants in carrots may be able to fight leukemia cells and may play a role in reducing your risk of some of the most widespread types of cancers, including ovarian and breast cancer. 2. Tomatoes Cooked tomatoes are especially good for the guys in your life they contain a carotenoid called lycopene that might lower prostate cancer. The juicy red fruit can help guard the DNA in your cells from damage that can lead to cancer. Tomatoes contain a particularly high concentration of an effective antioxidant called lycopene. Your body may absorb lycopene better from processed tomato foods such as sauce, which means that whole-wheat pasta with marinara sauce could be a delicious way to get your dose of cancer-fighting foods. 3. Fiber Fare rich in fiber, including certain cereals, root and other types of vegetables, and legumes, seems to protect against colon cancer. Every 10 grams of fiber you eat is associated with a 10 percent reduced risk of colorectal cancer and a 5 percent fall in breast cancer risk, says a study published in the Annals of Oncology. In addition to the anti-cancer effects of fiber, the foods that contain it like veggies and fruits—are also rich in antioxidants and phytochemicals that could further reduce your odds, notes Sheth. Read even more about your diet and cancer risk. 4. Garlic The World Health Organization advises adding about a clove a day to foods; it may lower your risk of colon, stomach and breast cancers. Allium vegetables, especially garlic, and their bioactive sulfur compounds are believed to have effects at each stage of cancer formation and affect many biological processes that modify cancer risk. 5. Turmeric Turmeric May Reduce Cancer Risk. This orange-colored spice, a staple in Indian curries, contains an ingredient called curcumin (not the same as cumin) that may be useful in reducing cancer risk. According to the American Cancer Society, curcumin can inhibit some kinds of cancer cells in laboratory studies and slow the spread of cancer or shrink tumors in some animals. This cancer-fighting food is easy to find in grocery stores, and you can use it in a variety of recipes on your anti-cancer diet. 6. Berries The ORAC scores of nearly all berries are very high, making them some of the top high-antioxidant foods in the world. Blueberries, raspberries, cherries, strawberries, goji berries, camu camu and blackberries are easy to find and use in numerous types of recipes which is good news considering they supply vitamin C, vitamin A and gallic acid, a powerful antifungal/antiviral agent that increases immunity. 7. Organic Meats Organic meats including beef or chicken liver are recommended on many cancer-fighting diets since they’re considered some of the most nutrient-dense foods on the planet and extremely high in vitamin B12. Please Subscribe Our Channel: https://goo.gl/mdmvhj ☯ Knowledge Gain From https://draxe.com/ https://www.everydayhealth.com/ http://www.eatingwell.com/ ☯ Disclaimer The substances and the advice included on Daily Cure channel are supplied for educational and general purposes only and can not constitute any medical, legal or other expert advice about any subject material. None of the info on our videos is really an alternative for an analysis and treatment from your wellbeing professional. Always seek the advice of a medical doctor or other qualified medical provider before starting any new diet plan or treatment and also with any questions that you may have about a medical condition. Should you have or suspect that you might have a health problem, promptly contact your medical care provide. Check Out Our Social Media 👉 Facebook: https://www.facebook.com/Dailycuretube/ 👉 Twitter: https://twitter.com/daily_cure 👉 G+: https://plus.google.com/116503399674097797593 👉 Pinterest: https://www.pinterest.com/dailycure/ 👉 Tumblr:https://dailycure.tumblr.com/ 👉 Blogger: https://thedailycures.blogspot.com/ #foodsforbreastcancer #Anticancerfood #cancerstoppingfoods
Views: 125476 Daily Cure
Harold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.
Views: 110 Targeted Oncology
Dr Ann Pittier, radiation oncologist, explains how animal products promote breast cancer, and how a plant-based diet can help prevent breast cancer recurrence. Dr Joseph Marquez, urologist, explains how he talks to patients about their diet and the potential for a plant-based diet to prevent and treat Prostate Cancer & Erectile Dysfunction. See http://www.vegetarianprescription.org for medical studies on the use of plant-based diets to treat and prevent disease. Hosted at Seattle's Vegfest on April 1, 2017, by Vegetarians of Washington. http://www.vegofwa.org
Views: 76 Plant-Based Diets in Medicine
Discover what your odds of developing breast cancer in your opposite breast are from breast cancer expert Dr. Jay Harness. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Views: 34284 Breast Cancer Answers®
Dr Hecht talks to ecancer at ASCO 2013 about the Translational Research in Oncology (TRO) collaboration using lapatinib in combination with chemotherapy.
Views: 227 ecancer
http://www.howdini.com/howdini-video-7307820.html How to recognize inflammatory breast cancer symptoms Not all breast cancer involves a lump. There is a rare, but serious form known as inflammatory breast cancer whose symptoms are unique. Dr. Anne Moore, a leading breast oncologist, describes the symptoms and treatment for inflammatory breast cancer.
Views: 41797 Howdini
Dr. Susan Moody talks about treating women with breast cancer in the Breast Oncology Center at Dana-Farber/Brigham and Women's Cancer Center. She discusses how she works with new patients and her work researching drug resistance and potential new breast cancer treatments. Learn more about Dr. Moody and her colleagues at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx
Views: 579 Dana-Farber Cancer Institute
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams.
Views: 137 European Medical Group
Ike was diagnosed with HER2-positive breast cancer at the age of 38. Fortunately, she was diagnosed at an early stage, before the cancer had spread to other parts of her body. Early diagnosis meant that she could have surgery and other treatments to remove the cancer and help reduce the chances of it returning. In this video, Ike shares her powerful story of awareness, advocacy and hope. Since her diagnosis, Ike has been focused on raising awareness about breast cancer and the importance of early diagnosis. She has been involved in a number of projects with Roche, providing valuable insights that help us better understand and address patients’ needs. To learn more, visit https://www.roche.com/breast-cancer. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 15621 Roche
Amy, a breast cancer survivor, describes her experience using Genomic Health's Oncotype DX DCIS Breast Cancer Score to personalize her treatment options. Share this video with your loved ones to help empower other women facing a DCIS (ductal carcinoma in situ) breast cancer diagnosis to ask for personalized treatment. For more information, please visit: www.genomichealth.com www.oncotypedx.com
Views: 8312 Genomic Health, Inc.
Eric Winer, MD, Director of the Breast Oncology Center at the Susan F. Smith Center for Women’s Cancers, Chief of the Division of Women’s Cancers, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute, discussed how Boston Marathon© Jimmy Fund Walk presented by Hyundai participants benefit our 50/50 balance of research and patient care at our Fourth Annual Summit on Fundraising.
Views: 620 The Jimmy Fund
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer. Mittendorf says initially there was the HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) that proved to be immunogenic. She says in a recent study, her and her colleagues combined E75 with GMCSF to help prevent recurrence. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 662 Targeted Oncology
At the American Society of Clinical Oncology (ASCO) 2012, Elizabeth Ann Mittendorf, MD, MD Anderson, discusses breast cancer and AE-37.
Views: 1072 Oncology.TV
Envita is a leading cancer, Lyme disease, and chronic disease Unipathic treatment center in Scottsdale, Arizona. Our goal is to use the best of real time cancer and Lyme disease diagnostics to determine the best integrative cancer and Lyme disease treatments from around the world to help our patients receive a viable 2nd opinion. Upon discovering a lump in her breast and receiving a mammogram, Ashley was diagnosed with stage two breast cancer. Ashley was shocked to receive this diagnosis because of her healthy lifestyle, she began to seek out treatment. Ashley visited MD Anderson and Texas Oncology where she received the same protocol for treatment. Fearing the damage these treatments would cause to her body she began to search out an alternative. Having heard from her mother about a friend who had been treated at Envita 14 years prior and was still in remission, Ashley decided Envita was the clinic she needed to get well. She is currently in remission. ---------------------------------------------------------------------------------------------- Be sure to visit and subscribe to our channel for other informative videos: https://www.youtube.com/c/EnvitaNaturalMedicalCenterScottsdale To get a hold of a patient care coordinator today call us at: 1-866-830-4576 To receive information about a condition you may be dealing with visit https://www.envita.com/contact Visit out website to learn more: https://www.envita.com/ For cancer treatment info: https://www.envita.com/conditions/cancer For Envita's articles on cancer visit: https://www.envita.com/cancer For Lyme disease treatment info: https://www.envita.com/conditions/lyme-disease For Envita's articles on Lyme disease visit: https://www.envita.com/lyme-disease Facebook: https://www.facebook.com/Envita Twitter: https://twitter.com/envitamedical Google+: https://plus.google.com/+EnvitaNaturalMedicalCenterScottsdale Tumblr: https://envitamedicalcenters.tumblr.com/ Pinterest: https://www.pinterest.com/envitamedicalce/ Vimeo: https://vimeo.com/user10286984
Views: 16302 Envita Medical Center
The results of the Oncotype DX® Breast Cancer Assay (for invasive Breast cancer) are provided as a breast Cancer Recurrence Score result (a number between 0 to 100). This number corresponds to a specific likelihood that a woman's breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman's breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Dr. Hope Rugo discusses how the Recurrence Score result of the Oncotype DX Breast Cancer Assay could influence treatment decisions, especially in the intermediate Recurrence Score group. She confirms, from her experience, that the Oncotype DX Breast Cancer Assay Recurrence Score result reduces physicians' and patients' anxiety regarding their optimal treatment decisions. _______________________________________________________ Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Views: 732 Genomic Health, Inc.
Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer. More on breast cancer: http://www.onclive.com/specialty/breast-cancer
Views: 157 OncLiveTV
René Syler with Dr. Anne Moore, Medical Director of Breast Oncology Program at the Weill Medical College of Cornell University and Attending Physician at The New York Presbyterian Hospital. René Syler, Ambassador for Susan G. Komen for the Cure, leads off a series of how-to video discussions produced in conjunction with Memorial Sloan-Kettering Cancer Center, the Weill Medical College of Cornell University and Howdini.com.
Views: 1337 Susan G. Komen®
By: Erin Nichols -- Millions of American women are diagnosed with breast cancer every year, but now there's new hope for survival thanks to a medical breakthrough that's revolutionizing the way patients are treated. I was diagnosed almost to the day one year ago, said Corina Uribe. Uribe never imagined she would be diagnosed with breast cancer. I went to my scheduled mammogram and within the hour I was having the biopsy done, she said. Uribe went to see Dr. Jayasree Rao at Oncology San Antonio. Dr. Rao introduced her to a new group of tests called the Blueprint molecular test and the Mammaprint test, which allowed Dr. Rao to customize her treatment. Thankfully it was determined I did not need chemotherapy as part of my treatment, Uribe said. I'm very grateful. When I meet a patient I tell them not all breast cancers are the same and we are going to find the best care based on everything included the tumors specificity, said Dr. Rao. The tests work like this: doctors take a sample of a breast tumor, similar to a biopsy. Next, the sample is tested on a molecular level. Doctors can then use the tumor's own cellular make-up to determine what the next step in treatment will be. Even before the surgery, the doctor was able to see if these patients needed chemotherapy or not, and gave them the ability to categorize differently, said Dr. Rao. Depending on the results, Dr. Rao says patients may not even need a mastectomy. If there's one cancer we have made large strides it's breast cancer, and I think it's made large strides for other cancers to follow that, said Dr. Rao. Dr. Rao hopes the tests become part of the standard treatment for breast cancer care. Uribe says shes breast cancer free. It's a wonderful Christmas present, Uribe said. I couldn't ask for anything else. The tests will be presented at the San Antonio Breast Cancer Symposium next week. If you've been recently diagnosed with breast cancer and are interested in learning more about the test talk, to your oncologist.
Views: 266 FOX San Antonio
From ASCO 2014, Elizabeth A. Mittendorf, M.D., Ph.D., an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center discusses the primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Views: 1280 GenerexBiotechnology
Elizabeth Mittendorf, MD, PhD, assistant professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 154 Targeted Oncology
Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer. In her presentation at the 12th International Congress on the Future of Breast Cancer from July 18-20, 2013, in Huntington Beach, CA, Mittendorf spoke about HER2-targeted vaccine therapies. Provenge, for the treatment of metastatic castration-resistant prostate cancer, is the only FDA-approved cancer vaccine, Mittendorf notes. Treatment with Provenge involves leukapheresis, blood manipulation, and administration into the patient. This is an intricate and very expensive process, Mittendorf says. A peptide is a small piece of a protein, Mittendorf says, but is large enough to be recognized by the immune system. A peptide vaccine is given as a simple subdermal shot once per month for six months, followed by booster inoculations. If the peptide vaccine approach is proven to be efficacious, it would be cost-effective and simple to produce, making it more widely used than complex vaccine constructions. On the other hand, Mittendorf notes, peptide vaccines probably will not stimulate enough of an immune response to take care of an aggressive disease, which is why they are being investigated in the adjuvant setting. See more at: http://www.onclive.com/onclive-tv/Dr-Mittendorf-on-Peptide-Vaccines-for-Breast-Cancer#sthash.SnQDP7eG.k73IeORd.dpuf
Views: 991 Galena Biopharma
Andrew D. Seidman, MD, a professor of medicine at the Weill Cornell Cancer Center and an attending physician at the Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 41 Targeted Oncology
Anne Moore, M.D., the Director of the Weill Cornell Breast Center at NewYork-Presbyterian/Weill Cornell Medical Center in New York City, discusses innovations in treatment for patients with breast cancer. You can learn more about Dr. Moore at: http://www.weillcornell.org/annemoore/index.html
Views: 4763 NewYork-Presbyterian Hospital
Dr. Hope Rugo discusses the chemotherapy agent, Eribulin and the results of a recent study focused on breast cancer patients with advanced disease. We also question if she thinks this is the end for chemotherapy agents in the treatment of breast cancer? This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Rugo is a Clinical Professor in the Department of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center.
Views: 518 Vital Options International
Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways. Seidman says historically treatment and management of breast cancer has been accomplished with chemotherapy, endocrine therapy and HER2-targeted therapy. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 98 Targeted Oncology
Andrea got her breast cancer diagnosis many years into a struggle with fibromyalgia, so she had learned the value of having a high-quality pain team behind her. Now she made the switch to breast cancer and went looking for the best minds and the steadiest, most experienced hands in the areas of oncology, radiation, and surgery.
Views: 3677 Health Magazine
Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 1478 Targeted Oncology
Reshma Jagsi, MD, DPhil, associate professor, Department of Radiation Oncology, University of Michigan Health System, discusses the benefits of hypofractionated radiotherapy for patients with breast cancer.
Views: 203 OncLiveTV
C.Sessa comments on the efficacy of incorporating bevacizumab, as single agent and/or in combination with paclitaxel, for the treatment of recurrent locally advanced cervical cancer. ASCO13 http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Views: 565 European Society for Medical Oncology
Monica Morrow, MD, chief, Breast Service, Department of Surgery; Anne Burnett Windfohr Chair of Clinical Oncology, Memorial Sloan-Kettering Cancer Center, discusses the American College of Surgeons Oncology Group (ACOSOG) Z11 trial that sought to establish whether the elimination of axillary dissection was beneficial to patients. The Z11 trial was a prospective randomized trial for patients with T1 and T2 clinically node negative breast cancer, with positive sentinel nodes, treated with breast conserving surgery, and whole breast irradiation. After a 6.3-year follow-up the trial found that patients receiving axillary node dissection experienced 0.4% recurrence rates compared to 0.9% that did not. These findings did not establish a significant difference at preventing recurrence or improving survival between the two groups. These findings hold true only for the group examined in the trial. It is not suggested for patients undergoing a mastectomy or partial breast irradiation. The cancer cannot be locally advanced, have positive lymph nodes, or undergone neoadjuvant chemotherapy.
Views: 3028 OncLiveTV
http://www.howdini.com/howdini-video-7305985.html Breast cancer doctors: How to choose the right breast oncologist for you When a woman learns she has breast cancer, the news can be overwhelming, just when she needs to think clearly. Here are some vital tips to help you choose the right doctors for you, from leading breast cancer specialist Dr. Anne Moore.
Views: 1106 Howdini
Dr. Wendy Chen, medical oncologist with the Breast Oncology Program, discusses her work, why she welcomes family member participation in medical appointments, and the importance of individualized treatment plans. Learn more about how Dana-Farber's physicians treat breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx.
Views: 2000 Dana-Farber Cancer Institute
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.
Views: 52 OncLiveTV
Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.
Views: 276 OncLiveTV